Jennifer B. Green, MD

Incretin-based therapies for obesity and diabetes may be capable of treating a much wider range of diseases, including Alzheimer’s and Parkinson’s.

Jennifer B. Green, MD highlights the successful implementation of evidence-based therapies for high-risk patients with type 2 diabetes.

Expert clinicians discuss insulin therapy for treating type 2 diabetes and comment on what to look forward to in the future of diabetes care.

Drs Dennis Bruemmer and Jennifer Green review recent trial data on a novel combination of GIP and GLP1 receptor agonists to treat type 2 diabetes.

Thought leaders discuss recent advances in treatments for patients with type 2 diabetes with chronic kidney disease.

Dennis Bruemmer, MD, PhD, and Jennifer B. Green, MD, have a conversation about the use of SGLT2 inhibitors and GLP1 receptor agonists in treating type 2 diabetes.

Key opinion leaders review the recent ADA standards of care for type 2 diabetes.

Drs Jennifer Green and Dennis Bruemmer share advice for treating complicated cases of type 2 diabetes with comorbidities.

An expert cardiologist and endocrinologist explain the factors considered when creating a treatment plan for type 2 diabetes.

Jennifer B. Green, MD, and Dennis Bruemmer, MD, PhD, discuss the increasing prevalence of type 2 diabetes around the world, and the populations facing higher risk.